SOME: sintilimab plus chemotherapy followed by definitive local therapy for oligometastatic thoracic esophageal squamous cell carcinoma—a multicenter, prospective, open-label phase II trial | Synapse
May 15, 2026
SOME: sintilimab plus chemotherapy followed by definitive local therapy for oligometastatic thoracic esophageal squamous cell carcinoma—a multicenter, prospective, open-label phase II trial
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
: Chinese Clinical Trial Registry (http://www.chictr.org.cn), identifier is ChiCTR2500108825.